CN116726009B - 扑尔敏在制备治疗新生儿坏死性小肠结肠炎药物中的用途 - Google Patents
扑尔敏在制备治疗新生儿坏死性小肠结肠炎药物中的用途 Download PDFInfo
- Publication number
- CN116726009B CN116726009B CN202310933282.XA CN202310933282A CN116726009B CN 116726009 B CN116726009 B CN 116726009B CN 202310933282 A CN202310933282 A CN 202310933282A CN 116726009 B CN116726009 B CN 116726009B
- Authority
- CN
- China
- Prior art keywords
- chlorphenamine
- medicament
- necrotizing enterocolitis
- preparation
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 title claims abstract description 34
- 208000004995 necrotizing enterocolitis Diseases 0.000 title claims abstract description 27
- 229960003291 chlorphenamine Drugs 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 206010051606 Necrotising colitis Diseases 0.000 title claims abstract description 16
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 title claims abstract description 16
- 230000000968 intestinal effect Effects 0.000 claims description 17
- 238000009825 accumulation Methods 0.000 claims description 8
- 206010000060 Abdominal distension Diseases 0.000 claims description 5
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims description 5
- 208000035861 hematochezia Diseases 0.000 claims description 5
- 230000035699 permeability Effects 0.000 claims description 4
- 230000008719 thickening Effects 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 238000004393 prognosis Methods 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 3
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 3
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010012559 Developmental delay Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 206010022694 intestinal perforation Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于药物研究领域,具体涉及一种扑尔敏在制备治疗新生儿坏死性小肠结肠炎药物中的用途。经临床试验验证,扑尔敏对新生儿坏死性小肠结肠炎疗效显著,能够明显改善NEC患儿预后,并缩短病程。
Description
技术领域
本发明属于药物研究领域,具体涉及一种扑尔敏在制备治疗新生儿坏死性小肠结肠炎药物中的用途。
背景技术
新生儿坏死性小肠结肠炎(necrotizing enterocolitis ofnewborn,NEC)是以腹胀、呕吐、便血等为主要临床表现的急性坏死性肠道疾病,其发生与早产、肠黏膜缺氧缺血、感染、肠道菌群失调、不合理喂养、免疫应答异常等多种因素相关。其中因为食物蛋白诱导的NEC较为常见。有相关资料提出NEC受累积肠管主要表现为肠管壁水肿,炎性刺激与免疫异常应答往往可同时存在,所以除了传统的禁食、抗感染、营养支持治疗外,加入抗免疫功能异常治疗可有明显治疗效果。而当疾病发展至中重度时期时容易出现肠穿孔等危重合并症,需要借助外科手术进行治疗,这样会对新生儿造成外科创伤,不可避免影响新生儿的身体状况,严重者可出现短肠综合征、营养不良、严重贫血、神经系统发育障碍等极其影响远期预后的伴随症状,所以积极控制NEC进展至关重要。
因此,提供一种对新生儿坏死性小肠结肠炎疗效佳且治疗周期短的药物具有十分重要的价值。
发明内容
鉴于以上技术问题,本发明提供一种扑尔敏在制备治疗新生儿坏死性小肠结肠炎的药物中的用途。经临床试验验证,扑尔敏对新生儿坏死性小肠结肠炎疗效显著,能够明显改善NEC患儿预后,并缩短病程。
本发明第一方面,提供一种扑尔敏在制备治疗新生儿坏死性小肠结肠炎的药物中的用途。
优选地,所述扑尔敏用于制备改善腹胀的药物。
优选地,所述扑尔敏用于制备改善便血的药物。
优选地,所述扑尔敏用于制备改善肠壁积气的药物。
优选地,所述扑尔敏用于制备改善门脉积气的药物。
优选地,所述扑尔敏用于制备改善肠壁通透性的药物。
优选地,所述改善肠壁通透性是降低肠壁增厚幅度。
本发明第二方面,提供一种治疗新生儿坏死性小肠结肠炎的药物制剂,其包括所述扑尔敏,以及药学上可接受的辅料。
对比现有技术,本发明的有益效果如下:
本发明提供一种扑尔敏在制备治疗新生儿坏死性小肠结肠炎的药物中的用途。经临床试验验证,扑尔敏对新生儿坏死性小肠结肠炎疗效显著,能够明显改善NEC患儿预后,并缩短病程。
附图说明
图1为用药后的第1天(肠壁内有大量积气);
图2为用药后第1天(肝内积气);
图3为用药后的第2天(可见肠壁内少量积气);
图4为用药后第2天(肝内积气);
图5为用药后的第4天(肠壁积气基本消失);
图6为用药后第4天(肝内积气完全消失)。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
本发明所用扑尔敏为马来酸氯苯那敏片,马来酸氯苯那敏的分子式为C20H23ClN2O4。
临床试验
1、一般资料
将2019年10月~2022年11月期NEC住院早产儿进行分组干预。其中,2019年10月~2021年4月期间的NEC患儿为对照组,共49例,采用常规护理方式;2021年5月~2022年11月期间的NEC患儿为治疗组,共48例,采用扑尔敏干预方式。两组患儿的一般人口学资料比较均无统计学意义,具有可比性(P>0.05)。
2、诊断标准
参照《诸福棠实用儿科学》第八版。具体诊断标准见表1。
表1诊断标准
3、疗效评判标准
显效:相关临床表现症状及影像学、彩超学均好转;
有效:相关临床表现好转,影像学或彩超学提示未见好转;
无效:相关临床表现症状及影像学、彩超学均未好转;
恶化:相关临床表现症状及影像学、彩超学均加重。
4、治疗方法
对照组:禁食、胃肠减压、抗感染、肠外营养、维持内环境稳定以及必要的高级生命支持。
治疗组:对照组疗法+服用扑尔敏(扑尔敏用量1mg/kg/次,口服,1~2次/天)
疗程:根据NEC分期3天、7天、14天。
5、结果
5.1、相关临床表现症状比较
两组患儿在干预后腹胀、便血、肠壁积气、门脉积气的发生率、肠壁增厚幅度及抗生素的使用情况比较结果见表2~5。
表2两组患儿腹胀、便血发生率的比较
注:对照组:常规治疗;治疗组:扑尔敏干预
表3两组患儿肠壁积气、门脉积气发生率的比较
注:对照组:常规治疗;治疗组:扑尔敏干预
表4两组患儿肠壁增厚幅度的比
注:对照组:常规治疗;治疗组:扑尔敏干预
表5两组患儿抗生素使用情况比较
注:对照组:常规治疗;治疗组:扑尔敏干预
5.2、影像学、彩超学比较
结果见图1~6。
由图1~6可知,使用扑尔敏后能够明显新生儿坏死性小肠结肠炎的临床症状,提示扑尔敏可以作为治疗该类疾病的候选药物。
以上实施例仅用以说明本发明的技术方案,而非对其限制,尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。
Claims (7)
1.一种扑尔敏在制备治疗新生儿坏死性小肠结肠炎药物中的用途。
2.根据权利要求1所述的用途,其特征在于,所述扑尔敏用于制备改善腹胀的药物。
3.根据权利要求1所述的用途,其特征在于,所述扑尔敏用于制备改善便血的药物。
4.根据权利要求1所述的用途,其特征在于,所述扑尔敏用于制备改善肠壁积气的药物。
5.根据权利要求1所述的用途,其特征在于,所述扑尔敏用于制备改善门脉积气的药物。
6.根据权利要求1所述的用途,其特征在于,所述扑尔敏用于制备改善肠壁通透性的药物。
7.根据权利要求6所述的用途,其特征在于,所述改善肠壁通透性是降低肠壁增厚幅度。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310933282.XA CN116726009B (zh) | 2023-07-27 | 2023-07-27 | 扑尔敏在制备治疗新生儿坏死性小肠结肠炎药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310933282.XA CN116726009B (zh) | 2023-07-27 | 2023-07-27 | 扑尔敏在制备治疗新生儿坏死性小肠结肠炎药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116726009A CN116726009A (zh) | 2023-09-12 |
CN116726009B true CN116726009B (zh) | 2024-03-22 |
Family
ID=87904664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310933282.XA Active CN116726009B (zh) | 2023-07-27 | 2023-07-27 | 扑尔敏在制备治疗新生儿坏死性小肠结肠炎药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116726009B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101269038A (zh) * | 2008-05-16 | 2008-09-24 | 北京正大绿洲医药科技有限公司 | 扑尔敏缓释滴丸及其制备方法 |
CN104546949A (zh) * | 2015-01-19 | 2015-04-29 | 天津市宝坻区人民医院 | 一种治疗溃疡性结肠炎改进型复合药物配方 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050158303A1 (en) * | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
-
2023
- 2023-07-27 CN CN202310933282.XA patent/CN116726009B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101269038A (zh) * | 2008-05-16 | 2008-09-24 | 北京正大绿洲医药科技有限公司 | 扑尔敏缓释滴丸及其制备方法 |
CN104546949A (zh) * | 2015-01-19 | 2015-04-29 | 天津市宝坻区人民医院 | 一种治疗溃疡性结肠炎改进型复合药物配方 |
Non-Patent Citations (2)
Title |
---|
D M Hammerbeck.Selective hyperresponsiveness to ovalbumin-induced epithelial transport in inflamed guinea pig distal colon.Inflammation . .1993,第17卷(第6期),687-703. * |
Selective hyperresponsiveness to ovalbumin-induced epithelial transport in inflamed guinea pig distal colon;D M Hammerbeck;Inflammation .;第17卷(第6期);687-703 * |
Also Published As
Publication number | Publication date |
---|---|
CN116726009A (zh) | 2023-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3124725A1 (en) | Methods of treatment of inflammatory conditions and associated infections | |
CN116726009B (zh) | 扑尔敏在制备治疗新生儿坏死性小肠结肠炎药物中的用途 | |
CN112451540B (zh) | 抗幽门螺杆菌消化道内感染活性的透明质酸 | |
CN108836956B (zh) | 甘草查耳酮a在制备治疗鸡坏死性肠炎药物中的用途 | |
CN115119940A (zh) | 嗜酸乳杆菌LA85和乳双歧杆菌BLa80在抑制幽门螺旋杆菌上的应用 | |
CN112851774A (zh) | 一种多肽片段b及其应用 | |
CN113693237A (zh) | 一种干预乳糖不耐腹泻的新型天然固体干预剂及制备方法和应用 | |
CN110960561B (zh) | 用于调节妇科菌群平衡的益生菌组合物 | |
EA010199B1 (ru) | Антимикробная композиция для перорального введения | |
BR112021003578A2 (pt) | composição e método para erradicar helicobacter pylori | |
CN111166776A (zh) | 一种根除幽门螺杆菌引起的慢性胃炎的配方 | |
Baranov et al. | BIOLOGIC THERAPY IN PEDIATRIC RHEUMATOLOGY | |
Doedens et al. | Atypical cellulitis due to group B streptococcus | |
Li et al. | Therapeutic effect of Lactobacillus reuteri DSM 17938 on feeding intolerance in preterm infants | |
CN115025105B (zh) | 唾液酸在减轻体重和抑制体重增加中的应用 | |
CN117462525A (zh) | 衣康酸在治疗坏死性小肠结肠炎患者中的应用 | |
US20040096427A1 (en) | Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal dysfunctions including inflammation in the gastro-intestinal tract, neonatal necrotizing enterocolitis (nec) and bacterial sepsis | |
CN113694089A (zh) | 一种应用于防治仔猪白痢病的药物制剂 | |
CN117427061A (zh) | 一种木犀草素及其衍生物在制备抗肿瘤药物中的应用 | |
Liao et al. | Inclusion of Probiotics to Triple Antibiotic Therapy Improves the Outcome of Anti-Helicobacter pylori-Induced Peptic Ulcer. | |
Mondal et al. | Is Erythromycin Useful for Dysmotility of Prematurity?: A Randomised Controlled Trial in a Neonatal Unit of a Rural Medical College, India | |
CN101632762A (zh) | 治疗小儿口疮的中药药膏 | |
RU2193398C2 (ru) | Способ лечения дисбактериозов | |
CN1176667C (zh) | 一种治疗胃、肠疾病的药物及其制法 | |
Dheeb et al. | Incidence and Bacteriology of Acute Suppurative Parotitis in Patients Managed by Non Invasive Ventilation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |